Citation Information :
Shawky HA, Ahmed NM, Essawy MM, Basha SM. Histological and Biochemical Evaluation of Silibinin in Treatment of Periodontitis Induced in Rats with Liver Cirrhosis. J Contemp Dent Pract 2024; 25 (7):631-638.
Aim: This study aimed to evaluate the impact of silibinin as a therapeutic agent on ligature-induced periodontitis in rats with liver cirrhosis.
Materials and methods: Twenty-five Wistar rats were enrolled in this study. Group A (Control) included eight rats. The other 17 rats received CCl4 to develop cirrhosis, which was confirmed by sacrificing one of the rats and performing a histological examination of its liver tissue. Periodontitis was induced in the remaining 16 rats then they were allocated into (n = 8) group B—periodontitis with cirrhosis and group C—silibinin-treated group, 5 times/week starting from week 11 till week 14. Animals of the three groups were euthanized, and biochemical analysis comprising of liver functions assessment (serum levels of glutamate-pyruvate transaminase, serum levels of glutamate-oxalate transaminase, TIMP1) and oxidative stress index [MDA, nitric oxide (NO), superoxide dismutase (SOD), and catalase (CAT)] and histological examination were conducted by the end of week 14.
Results: Group C revealed a more organized orientation of the periodontal ligament (PDL) collagen fibers with a marked regain of the alveolar bone height compared to group B. Biochemical analysis confirmed the potent therapeutic effect of silibinin manifested by a significant improvement in the biochemical parameters: tissue inhibitor of metalloproteinase-1, MDA, NO levels, and antioxidant enzymes.
Conclusion: Group B was associated with the most unfavorable biochemical findings and the maximum periodontal destruction. Group C demonstrated a positive osteogenic capacity and a noteworthy improvement in biochemical findings, which were comparable to those of group A, which displayed normal and healthy findings.
Clinical significance: The study highlights the potential use of silibinin as a natural remedy with minimal side effects for treating periodontitis in rats with liver cirrhosis. The findings could be translated to human clinical trials, which may lead to new treatment strategies using silibinin as a targeted therapy or as adjunctive therapy to conventional periodontal treatment for patients with liver cirrhosis who are more susceptible to periodontitis.
Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 2020;18(12):2650–2666. DOI: 10.1016/j.cgh.2019.07.060.
Ladegaard Gronkjaer L, Holmstrup P, Schou S, Jepsen P, Vilstrup H. Severe periodontitis and higher cirrhosis mortality. United European Gastroenterol J 2018;6(1):73–80. DOI: 10.1177/205064061771 5846.
Saini R, Marawar PP, Shete S, et al. Periodontitis, a true infection. J Glob Infect Dis 2009;1(2):149–150. DOI: 10.4103/0974-777X.56251
Jeffcoat MK, Jeffcoat RL, Gladowski PA, et al. Impact of periodontal therapy on general health: Evidence from insurance data for five systemic conditions. Am J Prev Med 2014;47(2):166–174. DOI: 10.1016/j.amepre.2014.04.001.
Costa FO, Lages EJP, Lages EMB, et al. Periodontitis in individuals with liver cirrhosis: A case-control study. J Clin Periodontol 2019;46(10):991–998. DOI: 10.1111/jcpe.13172.
Apostolova N, Blas-Garcia A, V Esplugues J. Mitochondria sentencing about cellular life and death: A matter of oxidative stress. Curr Pharm Des 2011;17(36):4047–4060. DOI: 10.2174/138161211798764924.
Edeas M, Attaf D, Mailfert AS, et al. Maillard reaction, mitochondria and oxidative stress: Potential role of antioxidants. Pathol Biol (Paris). 2010;58(3):220–225. DOI: 10.1016/j.patbio.2009.09.011.
Wang Y, Andrukhov O, Rausch-Fan X. Oxidative stress and antioxidant system in periodontitis. Front Physiol 2017;8:910. DOI: 10.3389/fphys.2017.00910.
Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61(14):2035–2063. DOI: 10.2165/00003495-200161140-00003.
Federico A, Dallio M, Loguercio C. Silymarin/silybin and chronic liver disease: A marriage of many years. Molecules 2017;22(2):191. DOI: 10.3390/molecules22020191.
Council NR, Earth Do, Studies L, Research IfLA, Care CftUotGft, Animals UoL. Guide for the care and use of laboratory animals. 2010. DOI: 10.17226/12910.
Shawky HA, Essawy MM. Myricitrin: A promising herbal therapy for periodontitis in immunosuppressed status. Saudi Dent J 2023;35(5):515–524. DOI: 10.1016/j.sdentj.2023.04.002.
Al-Seeni MN, El Rabey HA, Zamzami MA, et al. The hepatoprotective activity of olive oil and Nigella sativa oil against CCl(4) induced hepatotoxicity in male rats. BMC Complement Altern Med 2016;16(1):438. DOI: 10.1186/s12906-016-1422-4.
Lin P, Niimi H, Ohsugi Y, et al. Application of ligature-induced periodontitis in mice to explore the molecular mechanism of periodontal disease. Int J Mol Sci 2021;22(16):438. DOI: 10.3390/ijms22168900.
Clichici S, Olteanu D, Nagy AL, et al. Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl(4)-treated rats. J Med Food 2015;18(3):290–298. DOI: 10.1089/jmf.2013.0179.
Popa GV, Costache A, Badea O, et al. Histopathological and immunohistochemical study of periodontal changes in chronic smokers. Rom J Morphol Embryol 2021;62(1):209–217. DOI: 10.47162/RJME.62.1.20.
Underwood W, Anthony RJRoM. AVMA guidelines for the euthanasia of animals: 2020 edition. 2020;2013(30):2020–2021.
Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957;28(1):56–63. DOI: 10.1093/ajcp/28.1.56.
Lin S-Y, Xu D, Du X-X, et al. Protective effects of salidroside against carbon tetrachloride (CCl4)-induced liver injury by initiating mitochondria to resist oxidative stress in mice. Int J Mol Sci 2019;20(13):3187. DOI: 10.3390/ijms20133187.
de Molon RS, Park CH, Jin Q, Sugai J, et al. Characterization of ligature-induced experimental periodontitis. Microsc Res Tech 2018;81(12):1412–1421. DOI: 10.1002/jemt.23101.
Andrade RSB, Franca LFC, Pessoa LDS, et al. High-fat diet aggravates the liver disease caused by periodontitis in rats. J Periodontol 2019;90(9):1023–1031. DOI: 10.1002/JPER.18-0564.
Jaiswal G, Deo V, Bhongade M, et al. Serum alkaline phosphatase: A potential marker in the progression of periodontal disease in cirrhosis patients. Quintessence Int 2011;42(4):345–348. PMID: 21516281.
Li X, Zhou R, Han Y, et al. Silibinin attenuates experimental periodontitis by downregulation of inflammation and oxidative stress. Oxid Med Cell Longev 2023;2023:5617800. DOI: 10.1155/2023/5617800.
Huang RY, Chang HY, Chih SM, et al. Silibinin alleviates inflammation-induced bone loss by modulating biological interaction between human gingival fibroblasts and monocytes. J Periodontol 2023;94(7):905–918. DOI: 10.1002/JPER.22-0535.
Kisseleva T, Cong M, Paik Y, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA 2012;109(24):9448–9453. DOI: 10.1073/pnas.1201840109.
Mirzaei E, Sabetian G, Masjedi M, et al. The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: A randomized double blinded placebo-controlled clinical trial. Clin Exp Hepatol 2021;7(2):149–155. DOI: 10.5114/ceh.2021.107067.
Hemmann S, Graf J, Roderfeld M, et al. Expression of MMPs and TIMPs in liver fibrosis – A systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007;46(5):955–975. DOI: 10.1016/j.jhep.2007.02.003.
Thiele ND, Wirth JW, Steins D, et al. TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice. Sci Rep 2017;7(1):714. DOI: 10.1038/s41598-017-00671-1.
Busk TM, Bendtsen F, Nielsen HJ, et al. TIMP-1 in patients with cirrhosis: Relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scand J Gastroenterol 2014;49(9):1103–1110. DOI: 10.3109/00365521.2014.934910.
Nie QH, Duan GR, Luo XD, et al. Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol 2004;10(1):86–90. DOI: 10.3748/wjg.v10.i1.86.
Kara E, Coskun T, Kaya Y, et al. Effects of silymarin and pentoxifylline on matrix metalloproteinase-1 and -2 expression and apoptosis in experimental hepatic fibrosis. Curr Ther Res Clin Exp 2008;69(6):488–502. DOI: 10.1016/j.curtheres.2008.12.003.
Canakci CF, Cicek Y, Yildirim A, et al. Increased levels of 8-hydroxydeoxyguanosine and malondialdehyde and its relationship with antioxidant enzymes in saliva of periodontitis patients. Eur J Dent 2009;3(2):100–106. PMID: 19421389.
Lu P, Mamiya T, Lu LL, et al. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol 2009;157(7):1270-1277. DOI: 10.1111/j.1476-5381.2009.00295.x.
Veljovic T, Djuric M, Mirnic J, et al. Lipid peroxidation levels in saliva and plasma of patients suffering from periodontitis. J Clin Med 2022;11(13):3617. DOI: 10.3390/jcm11133617.
Parwani SR, Chitnis PJ, Parwani RN. Salivary nitric oxide levels in inflammatory periodontal disease – A case-control and interventional study. Int J Dent Hyg 2012;10(1):67–73. DOI: 10.1111/j.1601-5037.2011.00508.x.
Malekinejad H, Taheri-Brujerdi M, Janbaz-Acyabar H, et al. Silymarin regulates HIF-1α and iNOS expression in the brain and gills of hypoxic-reoxygenated rainbow trout oncorhynchus mykiss. Aquat Biol 2012;15(3):261–273. DOI: 10.3354/ab00427.
Narendra S, Das UK, Tripathy SK, et al. Superoxide dismutase, uric acid, total antioxidant status, and lipid peroxidation assay in chronic and aggressive periodontitis patients. J Contemp Dent Pract 2018;19(7):874–880. PMID: 30066694.
Ayazoglu Demir E, Mentese A, Kucuk H, et al. The therapeutic effect of silibinin against 5-fluorouracil-induced ovarian toxicity in rats. J Biochem Mol Toxicol 2023;37(9):e23408. DOI: 10.1002/jbt.23408.